Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

PURPOSE A subset of head and neck cancers is associated with the human papillomavirus (HPV). Viral infection is closely correlated with expression of p16(INK4A) in these tumors. We evaluated p16(INK4A) as a prognostic marker of treatment response and survival in a well-defined and prospectively collected cohort of patients treated solely with conventional radiotherapy in the Danish Head and Neck Cancer Group (DAHANCA) 5 trial. PATIENTS AND METHODS Immunohistochemical expression of p16(INK4A) was analyzed in pretreatment paraffin-embedded tumor blocks from 156 patients treated with conventional primary radiotherapy alone. The influence of p16(INK4A) status on locoregional tumor control, disease-specific survival, and overall survival after radiotherapy was evaluated. RESULTS p16(INK4A) positivity was found in 35 tumors (22%). Tumor-positivity for p16(INK4A) was significantly correlated with improved locoregional tumor control (5-year actuarial values 58% v 28%; P = .0005), improved disease-specific survival (72% v 34%; P = .0006), and improved overall survival (62% v 26%; P = .0003). In multivariate analysis, p16(INK4A) remained a strong independent prognostic factor for locoregional failure (hazard ratio [HR], 0.35; 95% CI, 0.19 to 0.64), disease-specific death (HR, 0.36; 95% CI, 0.20 to 0.64), and overall death (HR, 0.44; 95% CI, 0.28 to 0.68). CONCLUSION Expression of p16(INK4A) has a major impact on treatment response and survival in patients with head and neck cancer treated with conventional radiotherapy.

[1]  S. Kösling.  Trends in head and neck radiology , 2011, European Radiology.

[2]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Karamouzis,et al.  Head and neck cancer , 2008, The Lancet.

[4]  J. Overgaard,et al.  Effect of HPV on Treatment Outcome and Survival in Oropharyngeal Carcinoma - a Subgroup Analysis of the Randomized DAHANCA 5&7 Trials , 2008 .

[5]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[6]  C. R. Leemans,et al.  A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen , 2007, International journal of cancer.

[7]  E. Sturgis,et al.  Trends in head and neck cancer incidence in relation to smoking prevalence , 2007, Cancer.

[8]  Jens Overgaard,et al.  Hypoxic radiosensitization: adored and ignored. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Overgaard,et al.  Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  H. Dienes,et al.  Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer , 2007, International journal of cancer.

[11]  D. Lindquist,et al.  The incidence of tonsillar cancer in Sweden is increasing , 2007, Acta oto-laryngologica.

[12]  L. Mariani,et al.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Munck‐Wikland,et al.  Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer , 2006, International journal of cancer.

[14]  Brian O'Sullivan,et al.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis , 2006, The Lancet.

[15]  M. Gillison,et al.  Clinical implications of human papillomavirus in head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Rimm,et al.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Overgaard,et al.  Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.

[18]  M. Zahurak,et al.  Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma , 2005, Clinical Cancer Research.

[19]  B. Schmidt,et al.  Tongue and tonsil carcinoma , 2005, Cancer.

[20]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[21]  C. R. Leemans,et al.  Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. , 2004, Journal of the National Cancer Institute.

[22]  Cai Grau,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial , 2003, The Lancet.

[23]  P. Fuchs,et al.  Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? , 2003, Medical Microbiology and Immunology.

[24]  Karl Münger,et al.  Human papillomavirus immortalization and transformation functions. , 2002, Virus research.

[25]  M. V. Doeberitz.  New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. , 2002 .

[26]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[27]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[28]  J. Pignon,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .

[29]  R. Biggar,et al.  Changing patterns of tonsillar squamous cell carcinoma in the United States , 2000, Cancer Causes & Control.

[30]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[31]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[32]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  J. Nevins,et al.  Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Unger,et al.  Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. , 1995, Human pathology.

[35]  R. Holm,et al.  Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix. , 1994, Journal of clinical pathology.

[36]  K. Cooper,et al.  Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation. , 1991, Journal of clinical pathology.

[37]  J. Overgaard,et al.  Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival. , 1986, International journal of radiation oncology, biology, physics.

[38]  F. Bosch,et al.  Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. , 1998, Cancer research.